Determinants of high-risk sexual behavior during post-exposure prophylaxis to prevent HIV infection

AIDS Behav. 2008 Nov;12(6):852-9. doi: 10.1007/s10461-007-9286-8. Epub 2007 Aug 8.

Abstract

Men who have sex with men (MSM) receiving non-occupational post-exposure prophylaxis (NPEP) to prevent HIV transmission completed interview-assisted questionnaires regarding high-risk behavior in the 6 months prior to NPEP and during the 28-day NPEP period. 21% of participants reported unprotected sex during NPEP, and 11% reported unprotected sex with HIV-positive or HIV status unknown partners. In univariate analyses, unprotected sex during NPEP was associated with prevention fatigue, depression, loss of loved ones to HIV, and a history of engagement with HIV/AIDS service organizations, e.g., receiving services from an HIV-related agency, donating money to HIV-related causes, and reading HIV-related magazines. Logistic regression analyses revealed that the strongest predictor of risk-taking during NPEP was HIV engagement. These data underscore the importance of combining chemoprophylaxis with behavioral interventions that support risk-reduction. Such interventions should not assume that those most engaged with HIV/AIDS service organizations are less likely to engage in risk behavior.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / analogs & derivatives
  • Adenine / therapeutic use
  • Anti-HIV Agents* / therapeutic use
  • Deoxycytidine / analogs & derivatives
  • Deoxycytidine / therapeutic use
  • Drug Therapy, Combination
  • Emtricitabine
  • HIV Infections / drug therapy
  • HIV Infections / prevention & control*
  • Homosexuality, Male*
  • Humans
  • Interviews as Topic
  • Lamivudine / therapeutic use
  • Male
  • Organophosphonates / therapeutic use
  • Reverse Transcriptase Inhibitors* / therapeutic use
  • Risk Factors
  • Risk-Taking*
  • Sexual Partners
  • Surveys and Questionnaires
  • Tenofovir
  • Treatment Outcome

Substances

  • Anti-HIV Agents
  • Organophosphonates
  • Reverse Transcriptase Inhibitors
  • Deoxycytidine
  • Lamivudine
  • Tenofovir
  • Emtricitabine
  • Adenine